Guides Collective
The Weekly Guide
Resources, research, and reflections — curated each week for the guides in our community.
JUL 17, 2026
From the Platform
What's new and coming to Guides Collective.
UX updates on Seeker Dashboard has begun! We'll be tackling the seeker journey first before improving the Guide Dashboard.
We're connecting National Ads to a marketing funnel we're developing. Using AI to assess the data and give us the marketing points to improve our outreach strategy.
We're developing some good creative ideas for our ad strategy. Stay tuned, you might see it appear on your socials soon.
Section 01
Personal Journeys
First-person accounts worth reading — perspectives that inform the work we do.
DOUBLEBLIND MAG · APRIL 22, 2026
The Dark Side of Psychedelic Healing, According to Erica Rex
Erica Rex's memoir traces childhood trauma, medical crises, and her own encounters with psychedelic therapy — and a hard-won argument that healing systems can just as easily become tools of exploitation. She makes the case that psychedelics amplify whatever's already there, and that trauma survivors need stricter safety structures, not fewer.
ESSENCE · JULY 22, 2025
Fall Apart Without Fear: Inside a Psilocybin Retreat Made for Women of Color
Writer Patrice Peck attended a psilocybin-assisted wellness retreat in Jamaica designed specifically for women of color, where guided ceremonies led to profound emotional release. She describes finally learning how to "fall apart without fear" — and healing with real cultural intentionality.
Section 02
From the Field
Perspectives and insights from leaders in the psychedelic space.
BIOPHARMA DIVE · JUNE 24, 2026
Wall Street Sees Psychedelics as "One of the Most Important Waves of Innovation" in Biotech
Cantor Fitzgerald analyst Joshua Schimmer says the psychedelics sector is entering rare territory — "we're seeing things we've really not seen before in psychiatric care, and it doesn't end with depression." Rather than treating rival companies' wins as competitive threats, Wall Street increasingly sees each clinical success — like Definium's recent LSD trial data — as validating the whole field at once.
PR NEWSWIRE · JUNE 29, 2026
Optimi's Psilocybin Is Now Reimbursed by Australian Insurers, With 750+ Clinicians Trained
Optimi Health shipped its third commercial batch of psilocybin capsules to Australia, where the treatment is now reimbursed by major public and private payers including the Department of Veterans' Affairs. More than 750 clinicians have been trained to administer the therapy, with no serious adverse events reported after two years of regulated use.
Section 03
Industry Headlines
What's happening in the psychedelic space this week.
BIOSPACE · JULY 14, 2026
FDA Finalizes Psychedelic Drug Guidance, Signals It's "Receptive" to Helping Companies Succeed
The FDA released finalized recommendations for psychedelic drug clinical trials, giving developers more flexibility in study design and abuse-potential assessments — including a fix for the "unblinding" problem that derailed an earlier MDMA therapy application. Compass Pathways' psilocybin treatment for depression could now be approved as early as this year under the more accommodating framework.
MARIJUANA MOMENT · JULY 13, 2026
Massachusetts House Passes Bill to Launch Five-Year Psychedelic Therapy Pilot Program
The Massachusetts House voted 148-2 to create a five-year pilot letting up to three licensed mental health clinics offer on-site psychedelic treatment, funded through a new Medical Psychedelics Fund. The measure still needs Senate approval and Governor Maura Healey's signature to become law.
MARIJUANA MOMENT · JULY 14, 2026
HHS and VA Sign Five-Year Agreement to Bring Psychedelic Therapy to Veterans
The Department of Health and Human Services and the VA signed a memorandum of understanding to collaborate on research, clinical development, and rollout of psychedelic treatments — including MDMA, psilocybin, and ibogaine — for veterans with serious mental health conditions. "We're not going to wait while promising treatments sit on the sidelines," said HHS Secretary Robert F. Kennedy Jr. at the signing.